Aromatase inhibitors are a class of drugs used primarily in the treatment of hormone-sensitive breast cancer in postmenopausal women. They work by blocking the aromatase enzyme, which converts androgens into estrogens, thereby reducing estrogen levels in the body. This is crucial, as many hormone-sensitive cancers thrive on estrogen.

Detailed information about Aromatase Inhibitors can be found at Aromatase Inhibitors Taking – a comprehensive resource for sports pharmacology in England.

1. Common Aromatase Inhibitors

Some of the commonly prescribed aromatase inhibitors include:

  1. Letrozole (Femara)
  2. Anastrozole (Arimidex)
  3. Exemestane (Aromasin)

2. Dosage Guidelines

Proper dosage of aromatase inhibitors can vary based on the specific drug, patient needs, and the condition being treated. Below are the typical dosage recommendations for the commonly used aromatase inhibitors:

  1. Letrozole:
    • Standard Dose: 2.5 mg orally once a day.
    • Duration: Usually taken for at least 5 years.
  2. Anastrozole:
    • Standard Dose: 1 mg orally once a day.
    • Duration: Usually taken for at least 5 years.
  3. Exemestane:
    • Standard Dose: 25 mg orally once a day.
    • Duration: Typically used for 5 years after initial treatment with surgery or radiation.

3. Important Considerations

When dosing aromatase inhibitors, healthcare providers consider several factors, including:

4. Side Effects

Aromatase inhibitors can cause side effects, including:

5. Conclusion

Understanding the dosage and administration of aromatase inhibitors is crucial for effective cancer treatment. It is essential for patients to follow their healthcare provider’s instructions and report any side effects. Regular follow-up visits should also be scheduled to monitor overall effectiveness and manage any adverse reactions.